|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDKN2 is deleted in a relevant number of tumor cell lines, but results of the studies in primary tumors are contradictory.
|
7987825 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Frequent homozygous deletions of this gene have been documented in cell lines derived from different types of tumors, including breast tumors, suggesting that CDKN2 is a tumor suppressor gene involved in a wide variety of human cancers.
|
7923151 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the inhibitor of cyclin-dependent kinase 4 (CDK4I; also known as p16INK4, multiple tumor suppressor 1, or CDKN2 gene) has been mapped to 9p21 and shown to be mutated or deleted in a large fraction of cell lines derived from many tumor types, including melanoma, suggesting that this gene could be a melanoma suppressor gene.
|
7923152 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have examined the sequence of CDKN2 in 154 tumor cell lines that are not homozygously deleted for CDKN2.
|
7700630 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Amplifications of CDK4 and CCND1 (cyclin D1) were observed in 11% and 4% of the sarcomas respectively, but never in tumours with CDKN2 deletions.
|
7640224 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also studied the growth rate of tumor cell lines following stable transfection of CDKN2 gene.
|
7494231 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of heterozygosity studies in melanoma and pancreatic carcinoma from gene carriers strongly support the view that CDKN2 is a general tumour suppressor gene predisposing not only to melanoma but also to other malignancies.
|
7640518 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cyclin-dependent kinase 4 (cdk4) inhibitor (p16INK4/MTS1/CDKN2) gene has been recently identified as a putative tumor suppressor gene because of the high frequency of homozygous deletion observed in numerous human tumor cell lines, including leukemias.
|
7630199 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p16Ink4/MTS1/CDKN2 is a cell-cycle regulatory inhibitor of cyclin-dependent kinase 4 (cdk4), and a candidate tumour suppressor whose gene on chromosome band 9p21 is frequently deleted or mutated in diverse types of cancer.
|
7705923 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Single-strand conformation variant analysis (SSCV) and direct sequencing of the variants revealed somatic CDKN2 mutations in 11 of 32 tumors (five frame-shift mutations, five nonsense mutations, and one missense mutation).
|
8589035 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitor of cyclin-dependent kinase 4, CDKN2 (also known as p16INK4 or MTS-1, multiple tumor suppressor gene 1), has been mapped to 9p21.
|
7478563 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data support a role for MTS1/p16/CDKN2 as a tumor suppressor gene in the in vivo evolution of GBMs.
|
7887443 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using this probe, FISH analysis of primary glioblastoma tumors revealed homozygous deletions of the CDKN2 region in 6 of 9 tumors (67%) whereas a yeast artificial chromosome probe containing the interferon type I (IFN) gene cluster was deleted in only 4 cases (44%).
|
7867008 |
1995 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Of 21 tumors analyzed, only 1 showed a mutation of probable consequence, suggesting that CDKN2 appears not to be the target of loss of heterozygosity and indicating the possible existence of another tumor suppressor gene within this region.
|
7796417 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recent data suggest that homozygous deletion of the cyclin-dependent kinase 4 inhibitor gene (CDKN2), a putative tumour suppressor gene located on chromosome 9p21, represents a common genetic event in human cancer.
|
8555065 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p16/CDKN2 gene has many features of a growth suppressor gene: it maps to 9p21, a frequent region of loss of heterozygozity in a variety of tumor types; it encodes an inhibitor of cyclin-dependent kinase 4; and its homozygous deletion is common in tumor-derived cell lines.
|
7882335 |
1995 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistent with the hypothesis that hypermethylation of the CDKN2 gene is a tumor-specific mechanism for gene inactivation, we observed hypomethylation at the exon 1 site exclusively in tumor lines that expressed p16INK4 or that had sustained inactivating point mutations within the CDKN2 open reading frame.
|
7566983 |
1995 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
In summary, inactivation of CDKN2 is implicated in the development of about 20% of NSCLC, but the possibility of another tumor suppressor gene on chromosome segment 9p21 important in lung cancer cannot be eliminated.
|
8589032 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Homozygous deletion of the CDKN2 gene was detected in only 1 tumour.
|
7591208 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p16 gene, also referred to as MTS1, INK4, CDK4I, or CDKN2, at chromosome 9p21 has recently been described as a tumor suppressor that may be involved in a wide range of tumors.
|
7718873 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequency of homozygous CDKN2 gene deletion in NSCLC cell lines is greater than that observed for any other known, or candidate, tumor suppressor gene.
|
7563154 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Single strand conformational polymorphism analysis of the entire coding region of the MTS1/CDKN2 gene revealed no mutation within MTS1/CDKN2 in any tumor.
|
7791990 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We conclude that hemizygous or homozygous deletions of the CDKN2 gene occur at high frequency in T-ALL and at low frequency in B-lineage ALL, supporting the role of this gene as a tumour suppressor, especially in T-ALL.
|
8547131 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p16INK4 tumor-suppressor gene (also known as CDKN2, CDK41 and MTS1) encodes a negative regulator of the cell cycle.
|
8690521 |
1996 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, four of the seven chondrosarcoma cell lines also showed deletions of the CDKN2 and/or MTS2 putative tumor suppressor genes, or the absence of the CDKN2 protein product.
|
8689637 |
1996 |